- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01634919
Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon Alpha-2a and Ribavirin
March 19, 2020 updated by: Won Kim, Seoul National University Boramae Hospital
A Single Center, Prospective Study Evaluating the Anti-fibrotic Effect of Combination Therapy of Peginterferon Alpha-2a Plus Ribavirin in Patients With Chronic Hepatitis C, Based on Histologic Changes and Noninvasive Fibrosis Assessments
•The purpose of this study is to compare the performance between liver biopsy and non-invasive fibrosis assessments evaluating anti-fibrotic efficacy of peginterferon plus ribavirin in patients with hepatitis C pre- and post-treatment
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- Patients with histologically advanced hepatitis C receiving peginterferon plus ribavirin combination therapy have showed 30-40% of a sustained virologic response (SVR) rate and 50% of histologic improvement.
- The histologic change of liver is the most important prognosticator to predict further clinical outcomes in advanced hepatitis C patients following peginterferon-based antiviral therapy.
- Although liver biopsy remains the gold standard for histologic assessment, it has several shortcomings in terms of poor repeatability due to its invasiveness and poor reproducibility due to sampling error and intra- or inter-observer variability.
- Treatment-naïve patients with chronic hepatitis C will receive PEGASYS® 180 mcg once weekly and ribavirin twice daily for 24 or 48 weeks depending on the genotype of hepatitis C virus (HCV).
- All subjects will be followed for up to 48 weeks after treatment cessation.
- Liver biopsy will be done at baseline and the end of follow-up for the evaluation of histologic response.
- Noninvasive tests for liver fibrosis (ARFI elastography, APRI, FIB-4, FibroTest®, and ELF test) will be assessed per 24 weeks during the whole study period.
- The results of this study will provide insight into the histo-physical link between histologic changes and liver stiffness dynamics during and after peginterferon alpha-2a plus ribavirin treatment in patients with advanced hepatitis C.
- Therefore, noninvasive fibrosis assessments may be useful to trace fibrosis outcomes in patients with advanced hepatitis C receiving antiviral therapy.
Study Type
Observational
Enrollment (Actual)
55
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 156-707
- SMG-SNU Boramae Medical Center
-
Seoul, Korea, Republic of, 156-707
- Seoul Metropolitan Government Boramae Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Hospital-based cohort
Description
Inclusion Criteria:
- Male and female subjects ≥20 years of age
- Subjects with positive anti-HCV Ab in sera
- Subjects with detectable HCV RNA by quantitative real time polymerase chain reaction (PCR) (> 50 IU/mL)
- Subjects without receiving any previous antiviral treatment
- Subjects undergoing radiologic studies (liver ultrasonography (USG), CT or MRI) to exclude the presence of hepatocellular carcinoma (HCC) within the last 1 year before enrolment
- All fertile males with partners of childbearing age and females must be using reliable contraception during the study and for 3 months after treatment completion
- Written informed consent should be obtained from all subjects.
Exclusion Criteria:
- History of any interferon (IFN)-based therapy before enrolment
- Positive test at screening for anti-hepatitis A virus (HAV) immunoglobulin M (IgM) Ab, HBsAg, anti-hepatitis D virus (HDV) Ab or anti- HIV Ab
- Histologically confirmed liver cirrhosis (F4 of fibrosis stage)
- If subjects have compromised liver function (Child-Pugh score >6)
- Signs or symptoms of hepatocellular carcinoma within the last 1 year before enrolment
- History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures, thalassemia)
- Women with ongoing pregnancy or who are breast feeding
- Male partner of potentially pregnant women
- Neutrophil count <1,500 cells/mm3 or platelet count <75,000 cells/mm3 at screening
- Hemoglobin <11 g/dL for females and <12 g/dL for men at screening
- Serum creatinine level >1.5 times the upper limit of normal at screening
- Evidence of immunosuppressive therapy
- History of severe psychiatric disease, especially depression.(Severe psychiatric disease is defined as major depression or psychosis, suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Chronic hepatitis C
|
acoustic radiation force impulse ultrasonography
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-fibrotic response
Time Frame: 48 weeks after the end of treatment
|
Anti-fibrotic response, indicated by a lack of histological worsening, defined as the stabilization or the improvement of at least one stage in the histologic fibrosis staging 48 weeks after the end of treatment
|
48 weeks after the end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Histologic and noninvasive fibrosis assessments
Time Frame: 48 weeks after the end of treatment
|
|
48 weeks after the end of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Won Kim, Ph.D, SMG-SNU Boramae Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2012
Primary Completion (Actual)
February 17, 2017
Study Completion (Actual)
February 9, 2018
Study Registration Dates
First Submitted
July 3, 2012
First Submitted That Met QC Criteria
July 3, 2012
First Posted (Estimate)
July 6, 2012
Study Record Updates
Last Update Posted (Actual)
March 20, 2020
Last Update Submitted That Met QC Criteria
March 19, 2020
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis, Chronic
- Hepatitis C, Chronic
Other Study ID Numbers
- 06-2012-74
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis C
-
Sohag UniversityRecruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Hospices Civils de LyonCompleted
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis cChina
-
Ascletis Pharmaceuticals Co., Ltd.CompletedChronic Hepatitis cChina
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
Clinical Trials on chronic hepatitis C
-
Hospital St. Joseph, Marseille, FranceCompleted
-
Centre Hospitalier Intercommunal CreteilAssociation Nationale des Hépato-Gastroentérologues des Hôpitaux GénérauxRecruiting
-
Yale UniversityTerminatedDe Novo Autoimmune Hepatitis
-
Beijing Ditan HospitalCompleted
-
CHU de ReimsCompleted
-
State University of New York at BuffaloCompleted
-
Piramal Enterprises LimitedMelanoma Research Foundation Breakthrough ConsortiumSuspendedAdvanced or Inoperable Malignant Melanoma With BRAF MutationUnited States
-
New York Institute of TechnologyCompleted
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Target PharmaSolutions, Inc.RecruitingLiver Diseases | Hepatitis B | HepatitisUnited States, Canada